Anticancer, antioxidant, and antimicrobial studies and molecular docking of a new hexanuclear Zn(II) complex, together with its X-ray crystal analysis.

A new hexanuclear Zn(II) complex with the ligand 2,2'-(piperazine-1,4-diyl)bis(ethan-1-amine), [L3Zn6(OH)6][ClO4]6·3MeOH·7H2O, was synthesized. The crystal structure of this complex showed that each Zn atom is in a distorted tetrahedral coordination environment, surrounded by two nitrogen atoms from each ligand and two hydroxide groups, each of which bridges to another Zn atom. The anticancer activities of the ligand and its metal complex against the breast cancer cell line (MCF-7) indicated that the zinc complex had a greater anticancer activity. The free ligand and its metal complex were evaluated for antioxidant activity using the DPPH scavenging method. In addition, the antibacterial activities of both compounds were screened against Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria. The interaction of these compounds with DNA and AChE was also investigated using molecular docking.

Complexation of drug amifampridine with Cu(II), Zn(II) and Cd(II) ions, and its dimerization with the magic of Mn(II) salts. Potential anti-COVID-19 and anticancer activities.

The different behaviors of the drug amifampridine (AMP) against Mn(II), Cu(II), Zn(II) and Cd(II) metal ions, in the presence and absence of tris(2-aminoethyl)amine (tren) was studied. The results showed that AMP successfully coordinates with Cu(II), Zn(II) and Cd(II) metal ions, but interestingly it undergoes an unexpected dimerization through a C-H activation in the presence of different Mn(II) salts. A four-coordinate complex of zinc(II), [Zn(AMP)2Cl2] (1), a binuclear complex of cadmium(II), [Cd2(AMP)2Cl4] (2), three five-coordinate tren-based metal complexes, [Cu(tren)(AMP)](ClO4)2 (8), [Zn(tren)(AMP)]Cl2 (9) and [Cd(tren)(AMP)](ClO4)2 (10), three pyridinium salts, [AmpDimer]X (X = Cl-, NO3-, ClO4-; (3, 4 & 5)), and also two four-coordinate metal complexes with this pyridinium cation, [Zn(AmpDimer)Cl3] (6) and [Cd(AmpDimer)Cl3] (7), were synthesized. All new compounds were characterized by elemental analysis and IR spectroscopy, and by 1H- and 13C-NMR spectroscopy (for 1, 2, 3, 6, 7, 9 & 10) and by X-ray crystal structure determinations (for 1, 3, 4, 5, 7, 8 & 10). Theoretical studies showed that the [M(tren)(AMP)]2+ cations act as pH-sensitive drug carriers of AMP and release it upon protonation. The molecular docking studies on the interaction of AMP and the above complexes/salts with DNA and the proteins of SARS-CoV-2 showed that the synthesized complexes/salts have greater anticancer and anti-covid-19 activities than AMP alone.

A tris(2-aminoethyl)amine-based zinc complex as a highly water-soluble drug carrier for the anti-COVID-19 drug favipiravir: a joint experimental and theoretical study.

Tris(2-aminoethyl)amine (tren) coordinates to a Zn(II) ion to form the [Zn(tren)]2+ cation that accepts a monodentate favipiravir (FAV) anion. The results of this work show that the FAV anion is capable of binding to the [Zn(tren)]2+ cation through either a nitrogen or an oxygen atom (N/O-coordination). The energy decomposition analysis shows that, interestingly, both the strength and nature of the bonds between the [Zn(tren)]2+ cation and the N/O-coordinated FAV anion are almost the same. X-ray crystal structure determinations confirmed the existence of two types of cations in the solid state, [Zn(tren)(N-FAV)]+ and [Zn(tren)(O-FAV)]+. The NMR data, in a DMSO solution, were consistent with either the N-coordinated or the O-coordinated complex, but not a mixture of the two linkage isomers. The theoretical data indicated that the [Zn(tren)(N-FAV)]+ and [Zn(tren)(O-FAV)]+ cations have very similar stability in the gas phase, and in H2O, CH3OH, and DMSO solutions, and can also easily convert from one linkage isomer to the other. The experimental and theoretical data showed that, upon protonation of the above cations under acidic conditions (pH ≈ 3 to 5.5), the drug FAV will be easily released and replaced by a Cl- anion, or an H2O molecule, which will coordinate to the zinc atom showing the potential of [Zn(tren)]2+ as a safe drug vehicle. Molecular docking studies using two well-known molecular docking packages show the relatively strong binding interactions of the [Zn(tren)(N-FAV)]+ and [Zn(tren)(O-FAV)]+ cations with DNA and viral protein macromolecules.

Theoretical and solid-state structures of three new macroacyclic Schiff base complexes and the investigation of their anticancer, antioxidant and antibacterial properties.

Three symmetrical macroacyclic Schiff base complexes were prepared from a ligand derived from the condensation reaction of 1,4-bis(2-aminophenyl)piperazine and salicylaldehyde (L) with Cu(ii), Ni(ii) and Co(ii) perchlorates. The ligand and the Schiff base complexes were characterized by elemental analyses, UV-vis, FT-IR and mass spectrometry, with the structure of [CoL] being determined by a single crystal X-ray structural analysis. In this complex, the cobalt is in a distorted trigonal prismatic coordination environment, surrounded by the six donor atoms of the deprotonated hexadentate ligand. In order to compare the experimental and theoretical data and determine structure parameters in all complexes, Density Functional Theory (DFT) calculations at the B3lyp and BP86 levels with Def2-TZVP basis set have been carried out. NBO and QTAIM analyses have been used to describe the nature of M-O and M-N bonding in these complexes. The synthesized complexes were screened for their antioxidant activities using the DPPH free radical scavenging assay while their bactericidal activity was evaluated by the paper disc diffusion method against both Gram-negative and Gram-positive bacteria, revealing strong antioxidant activities and moderate effectiveness against all bacteria tested. The cytotoxicity of the metal complexes was also investigated against AGS (gastric) and A549 (lung) adenocarcinoma cells.

The X-ray crystal structures, molecular docking and biological activities of two novel Cu(II) and Zn(II) complexes with a ligand having a potentially N4O2 donor set and two nitro phenyl rings as pendant arms.

A new ligand (L) containing two nitro phenyl rings as side chains was synthesized. The reaction of this ligand with copper(II) and zinc(II) metal ions gave complexes with different coordination environments. The free ligand and the metal complexes were characterized using a number of spectroscopic methods. The crystal structure of [ZnLBr]ClO4 showed that the Zn(II) ion was in a distorted square pyramidal environment. The crystal structure of [CuL](ClO4)2 showed that the Cu(II) ion is in a tetragonally distorted octahedral environment. Molecular docking studies with DNA indicated that the binding of L, [ZnLBr]ClO4 and [CuL](ClO4)2 involved the major groove of DNA, H-bonds and Vander Waals interactions. In contrast, the molecular docking of L, [ZnLBr]ClO4 and [CuL](ClO4)2 with human glutathione reductase (GR) showed that the dominant interactions of these compounds with GR were H-bonding, vander Waals and hydrophobic interactions. The antioxidant activity of the synthesized complexes was analyzed by the free radical scavenging activity using 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay with [CuL](ClO4)2 showing maximum activity. In addition, in vitro anticancer activity of the complexes against human breast MCF-7 cancer cell line was confirmed through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. All compounds showed a dose-dependent inhibitory effect on the growth of breast cancer cells with the inhibition activity of [CuL](ClO4)2 being more active than the other synthesized compounds. Furthermore, results from the antibacterial activity screening of the compounds against two Gram-positive and Gram-negative pathogenic bacteria by the micro-broth dilution and disk diffusion methods indicated that [CuL](ClO4)2 complex had the strongest antibacterial potential.